The combination of lonafarnib and sorafenib induces cyclin D1 degradation via ATG3-mediated autophagic flux in hepatocellular carcinoma cells

Combination treatment is a promising strategy to improve prognosis of hepatocellular carcinoma (HCC). Sorafenib is a traditional first-line agent approved for the treatment of advanced HCC, though with limited efficacy. Previously, we reported that lonafarnib, an orally bioavailable non-peptide inhi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Aging (Albany NY)
Autors principals: Wang, Jialiang, Wei, Huan, Huang, Yanlin, Chen, Dongmei, Zeng, Guofen, Lian, Yifan, Huang, Yuehua
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals 2019
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6710066/
https://ncbi.nlm.nih.gov/pubmed/31409760
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/aging.102165
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars